Generic Medicine Info
Indications and Dosage
Adult: Initially, 30-40 mg daily gradually increased if necessary. Maintenance: 30-90 mg daily as a single dose at night or in divided doses. Max: 200 mg/day.
Elderly: Initially, 30 mg slowly increased if necessary.
May be taken with or without food.
lactation, porphyria.
Special Precautions
Concurrent CNS depression; epilepsy; MAOIs withdrawal (at least 14 days after discontinuation); hepatic, renal or cardiac insufficiency; heart block or recent MI; angle-closure glaucoma; prostatic hyperplasia; diabetes mellitus; monitor blood count regularly.
Adverse Reactions
Drowsiness; liver dysfunction and jaundice; gynaecomastia; convulsions; hypomania; hypotension; hypertension; coma; arthralgia; oedema; tachycardia; bradycardia; vomiting; dizziness and ataxia; anticholinergic effects.
Potentially Fatal: Bone marrow suppression.
Symptoms are prolonged sedation, tachycardia and/or bradycardia. Treat with gastric lavage and supportive treatment.
Drug Interactions
Blood levels decreased by phenobarbitone, carbamazepine and phenytoin. Monitor blood pressure with antihypertensive therapy. Mianserin may antagonise the action of antiepileptics by lowering the convulsive threshold. CNS depressant effects enhance by alcohol, sedatives.
Potentially Fatal: Avoid MAOIs (and for 14 days after discontinuation).
Description: Mianserin is a structural analogue of serotonin (5-HT) with antagonistic effects at 5-HT2A, 5-HT2C and 5-HT3 receptors. Mianserin also blocks the inhibitory α2-receptors, thus leading to an increase in noradrenaline release.
Absorption: Readily absorbed from the GIT (oral).
Distribution: Widely distributed; crosses the blood-brain barrier; enters breast milk. Protein-binding: Extensive.
Metabolism: Extensively hepatic by aromatic hydroxylation, N-oxidation, N-demethylation.
Excretion: Urine (as metabolites), faeces (small amounts); 6-40 hrs (elimination half-life).
Disclaimer: This information is independently developed by MIMS based on Mianserin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
  • Mianserin Remedica
  • Servin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in